UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations Beyond Hormone Therapy for Breast Cancer: Who Needs Targeted Agents? Authors*: Hope S. Rugo Abstract #: Presentation Date/Time: Monday, June 6: 4:45 - 5:05 PM Location: Hall D1 Education Session: Targeted Therapies in Hormone Receptor-Positive Breast Cancer Citation: Rugo Research Interests: Dr. Rugo, Director of Breast Oncology & Clinical Trials Education, is PI on multiple clinical trials focusing on combining novel targeted therapeutics to improve the treatment of both early & late stage breast cancer (BC). She also works on studies to improve supportive care for early & late stage BC patients, including with UCSFs Advanced Breast Cancer Program. Dr. Rugo has numerous collaborations with large academic medical centers & consortia in order to expand the novel therapies available to patients. She was the director of the 2016 ASCO Breast Cancer Education Committee meeting, is a member of the Alliance & is a founding member of the Breast Cancer Research Consortium where she co-leads the triple negative working group. She is on the novel agents committee for the neoadjuvant multi-center I SPY2 trial. At UCSF, Dr. Rugo runs the Breast Forum, a bimonthly educational session for breast cancer patients, families & friends from throughout the bay area. http://cancer.ucsf.edu/people/profiles/rugo_hope.3648 __________________________________________________________________________ Emerging Insights Into Molecular Profiling Authors*: Wolfgang Michael Korn Abstract #: Presentation Date/Time: Monday, June 6: 5:39 - 5:51 PM Location: S406 Poster Discussion Session: Tumor Biology Citation: Korn Research Interests: Dr. Korn is a physician-scientist focused on the science and management of gastrointestinal cancers. Furthermore, he is the leader of the UCSF Molecular Oncology Initiative and founding Chair of the UCSF Molecular Tumor Board. He is principal investigator of clinical trials exploring new treatments for gastrointestinal cancers and conducts molecularly driven, disease-independent basket trials. His laboratory conducts research aimed at developing combination therapies for gastrointestinal cancers, based on the analysis of signal transduction and DNA repair pathways. http://cancer.ucsf.edu/gi/michael-korn *UCSF authors in bold 88
Presentations Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey. Authors*: Jeremy Howard Lewin, Daniel J Vis, Emile E. Voest, Rachel Liao, Petra M Nederlof, Barbara A. Conley, David B. Solit, Christopher L. Corless, Paulo V Campregher, Vanessa Tyrell, George Chong, Michael Watson, Sun Young Rha, Tim Maughan, Mark Caulfield, Vladimir Lazar, Laura Esserman, Charles L. Sawyers, Lillian L. Siu, Mark Lawler Abstract #: 11502 Presentation Date/Time: Tuesday, June 7: 8:00 - 11:00 AM Location: S100a Session: Tumor Biology Citation: J Clin Oncol 34, 2016 (suppl; abstr 11502) Esserman Research Interests: Dr. Esserman, surgeon & breast cancer oncology specialist, is the Carol Franc Buck Breast Care Center Director and co-leads the Breast Oncology Program. Her research is on improving healthcare value through integrating translational science, clinical informatics, systems re-engineering & clinical care delivery. In 2005, she received the NCI SPORE Investigator of the Year Award. In 2016 she received the Arbuckle Award from Stanford Graduate School of Business for Excellence in Management & was named to TIME’s 100 most influential people list. She is PI of the I-SPY TRIAL program, now a model for translational research & innovation in clinical trial design. She launched the Athena Breast Health Network to follow women from screening through treatment & outcomes, incorporating the latest in molecular testing & web-based tools. Athena just launched the WISDOM study to compare personalized vs annual breast cancer screening in 100,000 women and to predict who gets what kind of cancer. http://profiles.ucsf.edu/laura.esserman *UCSF authors in bold 89
Page 1 and 2:
UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4:
HDFCCC Overview A Designated NCI Co
Page 5 and 6:
HDFCCC Overview Core Capabilities S
Page 7 and 8:
Presentations Presentations View fu
Page 9 and 10:
Presentations Phase II trials of ce
Page 11 and 12:
Presentations CRS-207 immunotherapy
Page 13 and 14:
Presentations Long-term OS for pati
Page 15 and 16:
Presentations Randomized phase 2 st
Page 17 and 18:
Presentations Genomic Profiling to
Page 19 and 20:
Presentations Validating RNAseq-sig
Page 21 and 22:
Presentations Phase I/II study of V
Page 23 and 24:
Presentations Clinical and genomic
Page 25 and 26:
Presentations IMAAGEN trial safety
Page 27 and 28:
Presentations Immunogenicity of sip
Page 29 and 30:
Presentations Pembrolizumab for adv
Page 31 and 32:
Presentations Novel T cell exhausti
Page 33 and 34:
Presentations Correlation between m
Page 35 and 36:
Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56: Presentations Phase II trial with t
Page 57 and 58: Presentations Academic and Communit
Page 59 and 60: Presentations Prevention of everoli
Page 61 and 62: Presentations A phase 2 randomized,
Page 63 and 64: Presentations PD-L1 expression, Can
Page 65 and 66: Presentations The Heart of the Matt
Page 67 and 68: Presentations 4-year results of the
Page 69 and 70: Presentations Impact of landmark re
Page 71 and 72: Presentations Phase II study of ali
Page 73 and 74: Presentations Can lay health worker
Page 75 and 76: Presentations Medical Management of
Page 77 and 78: Presentations Prospective evaluatio
Page 79 and 80: Presentations A phase II randomized
Page 81 and 82: Presentations Early, molecular dete
Page 83 and 84: Presentations Metastatic melanoma,
Page 85 and 86: Presentations Three-year overall su
Page 87: Presentations Heritage: A phase III
Page 91 and 92: Presentations Controversies in Loca
Page 93 and 94: Presentations A pharmacodynamic stu
Page 95 and 96: Presentations Final results of a ph
Page 97 and 98: Presentations Comparative performan
Page 99 and 100: Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?